KTTAW - Pasithea Therapeutics Corp.
NYSE
$0.01
+$0.00 (+0.00%)
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
KTTAW Key Statistics
Market Cap
$0.00M
Employees
5
How KTTAW Compares to Peers
P/E Rank
N/A
of 1
Margin Rank
N/A
of 1
Growth Rank
N/A
of 1
Size Rank
N/A
of 1
Pasithea Therapeutics Corp. Company Information
- Headquarters
- 1111 Lincoln Road, Miami Beach, FL, United States, 33139, undefined
- Website
- www.pasithea.com